Practitioner (WHNP) Certification Exam |
1 00 Actual Board Questions and
Answers with rationales.
**1. Which hormone is primarily responsible for the LH
surge preceding ovulation?**
- A. Progesterone
- B. Estradiol
- C. Inhibin
- D. FSH
**Answer: B. Estradiol**
*Rationale:* Estradiol peaks mid-cycle and triggers the
LH surge that induces ovulation. This positive feedback
mechanism is essential for follicular rupture and
release of the oocyte .
---
**2. The most common cause of secondary
amenorrhea in reproductive-age women is:**
,- A. Hyperprolactinemia
- B. Thyroid disease
- C. Premature ovarian insufficiency
- D. Pregnancy
**Answer: D. Pregnancy**
*Rationale:* Pregnancy is always the first diagnosis to
rule out in secondary amenorrhea. A pregnancy test
should be obtained before initiating any other workup
.
---
**3. A 24-year-old presents with dysuria, sterile pyuria,
and mucopurulent cervical discharge. Most likely
cause?**
- A. Candida
- B. Trichomonas
- C. Chlamydia trachomatis
- D. Bacterial vaginosis
**Answer: C. Chlamydia trachomatis**
,*Rationale:* Chlamydia can produce dysuria and
sterile pyuria with minimal findings. Mucopurulent
cervicitis is a classic presentation .
---
**4. Which contraceptive method is contraindicated in
a woman with migraine with aura?**
- A. Copper IUD
- B. Combined oral contraceptives
- C. LNG-IUD
- D. Barrier methods
**Answer: B. Combined oral contraceptives**
*Rationale:* Estrogen increases the risk of stroke in
women with migraine with aura. Progestin-only
methods or non-hormonal options are preferred .
---
**5. A Pap smear shows ASC-US. HPV test is positive.
Appropriate next step?**
, - A. Repeat Pap in 3 years
- B. Colposcopy
- C. HPV vaccine
- D. Treat for CIN
**Answer: B. Colposcopy**
*Rationale:* ASC-US with positive high-risk HPV testing
requires colposcopy for further evaluation and possible
biopsy .
---
**6. First-line treatment for uncomplicated cystitis in
nonpregnant women?**
- A. Ciprofloxacin
- B. Nitrofurantoin
- C. Amoxicillin
- D. Doxycycline
**Answer: B. Nitrofurantoin**